Ji Yun Lee1, Ju-Hyun Lee1, Heeyoung Lee2, Beodeul Kang1, Ji-Won Kim1, Se Hyun Kim1, Jeong-Ok Lee1, Jin Won Kim1, Yu Jung Kim1, Keun-Wook Lee1, Jee Hyun Kim1, Hyoung Soo Choi3, Jong Seok Lee1, Soo-Mee Bang4. 1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 2. Center for Preventive Medicine and Public Health, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 3. Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 4. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Electronic address: smbang7@snu.ac.kr.
Abstract
INTRODUCTION: The epidemiology of immune thrombocytopenia (ITP) is not well characterized in an Asian population. MATERIALS AND METHODS: From July 2010 to June 2014, ITP patients were identified using the Korean Health Insurance Review and Assessment Service database. RESULTS: The overall incidence rate of ITP was 5.3 per 100,000 person-years (95% CI: 5.1-5.5). The overall incidence rate ratios of children under 15years old to adults and females to males were 3.8 (95% CI: 3.7-3.9) and 1.3 (95% CI: 1.2-1.4), respectively. Of the total 10,814 patients, 3388 patients (31%) needed treatment for ITP; of these, 54% continued treatment for more than three months. First-line therapy consisted of corticosteroids (CS) in 42%, immunoglobulin (IVIg) in 35%, CS with IVIg in 19%, and other immunosuppressive agents (ISA) in 4%. Among treated patients, 75% of adults and 33% of children continued treatment for more than three months. After three months, the most frequently used drug was CS alone in 63% of patients. Only 104 patients underwent splenectomy; of these, 51% received salvage treatment after a median of one month after surgery (range: 0-27). The proportion of patients who received platelet transfusions of 12units or more per month for at least two consecutive months was significantly higher among patients treated for more than three months compared with patients who completed treatment within three months. CONCLUSIONS: This population-based study is the first to describe the incidence of ITP and its treatment reality for patients in Korea.
INTRODUCTION: The epidemiology of immune thrombocytopenia (ITP) is not well characterized in an Asian population. MATERIALS AND METHODS: From July 2010 to June 2014, ITP patients were identified using the Korean Health Insurance Review and Assessment Service database. RESULTS: The overall incidence rate of ITP was 5.3 per 100,000 person-years (95% CI: 5.1-5.5). The overall incidence rate ratios of children under 15years old to adults and females to males were 3.8 (95% CI: 3.7-3.9) and 1.3 (95% CI: 1.2-1.4), respectively. Of the total 10,814 patients, 3388 patients (31%) needed treatment for ITP; of these, 54% continued treatment for more than three months. First-line therapy consisted of corticosteroids (CS) in 42%, immunoglobulin (IVIg) in 35%, CS with IVIg in 19%, and other immunosuppressive agents (ISA) in 4%. Among treated patients, 75% of adults and 33% of children continued treatment for more than three months. After three months, the most frequently used drug was CS alone in 63% of patients. Only 104 patients underwent splenectomy; of these, 51% received salvage treatment after a median of one month after surgery (range: 0-27). The proportion of patients who received platelet transfusions of 12units or more per month for at least two consecutive months was significantly higher among patients treated for more than three months compared with patients who completed treatment within three months. CONCLUSIONS: This population-based study is the first to describe the incidence of ITP and its treatment reality for patients in Korea.
Authors: Roszymah Hamzah; Nurasyikin Yusof; Nor Rafeah Tumian; Suria Abdul Aziz; Nur Syahida Mohammad Basri; Tze Shin Leong; Kim Wah Ho; Veena Selvaratnam; Sen Mui Tan; Siti Afiqah Muhamad Jamil Journal: J Blood Med Date: 2022-06-21
Authors: Qian Wang; Juan Li; Tian-Shu Yu; Yu Liu; Kai Li; Shuang Liu; Yang Liu; Qi Feng; Lei Zhang; Guo-Sheng Li; Lin-Lin Shao; Jun Peng; Ming Hou; Xin-Guang Liu Journal: Int J Biol Sci Date: 2019-10-23 Impact factor: 6.580